Cargando…

Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males

INTRODUCTION: For clinical decision-making, an estimate of remaining lifetime is needed to assess benefit against harm of a treatment during the remaining lifespan. Here, we describe how to predict life expectancy based on age, Charlson Comorbidity Index (CCI) and a Drug Comorbidity Index (DCI), whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Hemelrijck, Mieke, Ventimiglia, Eugenio, Robinson, David, Gedeborg, Rolf, Holmberg, Lars, Stattin, Pär, Garmo, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822781/ https://www.ncbi.nlm.nih.gov/pubmed/35135530 http://dx.doi.org/10.1186/s12911-022-01766-0

Ejemplares similares

How to measure temporal changes in care pathways for chronic diseases using health care registry data
por: Ventimiglia, Eugenio, et al.
Publicado: (2019)

How to model temporal changes in comorbidity for cancer patients using prospective cohort data
por: Lindhagen, Lars, et al.
Publicado: (2015)

Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
por: George, Gincy, et al.
Publicado: (2023)

Heterogeneity in risk of prostate cancer: A Swedish population‐based cohort study of competing risks and Type 2 diabetes mellitus
por: Häggström, Christel, et al.
Publicado: (2018)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
por: Fallara, Giuseppe, et al.
Publicado: (2021)

Prescription-based prediction of baseline mortality risk among older men
por: Gedeborg, Rolf, et al.
Publicado: (2020)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Causes of death in men with localized prostate cancer: a nationwide, population‐based study
por: Van Hemelrijck, Mieke, et al.
Publicado: (2015)

Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic
por: Gedeborg, Rolf, et al.
Publicado: (2021)

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study
por: Robinson, David, et al.
Publicado: (2013)

Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
por: Häggström, Christel, et al.
Publicado: (2016)

Mortality following Hip Fracture in Men with Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2013)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study
por: Wulaningsih, Wahyu, et al.
Publicado: (2012)

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory
por: Van Hemelrijck, Mieke, et al.
Publicado: (2016)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
por: Crawley, Danielle, et al.
Publicado: (2018)

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study
por: Beckmann, Kerri, et al.
Publicado: (2019)

Inorganic phosphate and the risk of cancer in the Swedish AMORIS study
por: Wulaningsih, Wahyu, et al.
Publicado: (2013)

Simulation model of disease incidence driven by diagnostic activity
por: Westerberg, Marcus, et al.
Publicado: (2020)

Susceptibility to SARS‐Cov‐2 infection and risk for severe COVID‐19 in patients with prostate cancer on androgen deprivation therapy
por: Gedeborg, Rolf, et al.
Publicado: (2022)

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
por: Corsini, Christian, et al.
Publicado: (2023)

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
por: Van Hemelrijck, Mieke, et al.
Publicado: (2010)

Iron metabolism and risk of cancer in the Swedish AMORIS study
por: Gaur, Anjali, et al.
Publicado: (2013)

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus
por: Crawley, Danielle, et al.
Publicado: (2018)

Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study
por: Wulaningsih, Wahyu, et al.
Publicado: (2013)

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0
por: Russell, Beth, et al.
Publicado: (2018)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories
por: Arthur, Rhonda, et al.
Publicado: (2016)

Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort
por: Melvin, Jennifer C, et al.
Publicado: (2017)

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
por: Lin, E., et al.
Publicado: (2020)

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: Lin, E., et al.
Publicado: (2021)

Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort
por: Bosco, Cecilia, et al.
Publicado: (2018)

The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries
por: Beckmann, Kerri, et al.
Publicado: (2021)

Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum
por: Ghoshal, Arunangshu, et al.
Publicado: (2017)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022)

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy
por: Orrason, Andri Wilberg, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4il0anr8n9j904p9mrn0bel553